TY  - JOUR
T1  - New drugs and safety: What happened to new active substances approved in canada between 1995 and 2010?
AU  - Lexchin J
Y1  - 2012/11/26
N1  - 10.1001/archinternmed.2012.4444
JO  - Archives of Internal Medicine
SP  - 1680
EP  - 1681
VL  - 172
IS  - 21
N2  - 
Monitoring the safety of drugs is increasingly recognized as a major issue in light of recent experience with products such as rofecoxib and rosiglitazone. Previous work found that the probability of new drugs either acquiring a black box safety warning or being withdrawn for safety reasons was 20% over a 25-year period1 and that oncology drugs that were granted a priority review were more likely to be subject to labeling changes than were drugs with a standard review.2

SN  - 0003-9926
M3  - doi: 10.1001/archinternmed.2012.4444
UR  - http://dx.doi.org/10.1001/archinternmed.2012.4444
ER  -